Australia seems poised to welcome potentially transformative treatment for obesity: Retatrutide. This dual compound – acting on both GLP-1 and GIP receptors – shows significant efficacy in global studies, pointing to meaningful decreases in BMI. While regulatory clearance hasn't occurred with the Therapeutic Goods Administration (TGA), many peo